Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.0-70.0,  Purpura, Thrombotic Thrombocytopenic Participant or legally authorized representative has provided signed informed consent greater than or equal to (>=) 18 years of age and/or assent form (signed by legal representative if participants is less than (<) 18 years of age) Participant is 0 to 70 years of age, inclusive, at the time of screening. (Participants < 18 years of age will be enrolled only after at least 5 adults (>= 18 years of age) each have at least 10 exposures with BAX 930 and reviewed by the Data Monitoring Committee (DMC). In France, no participants younger than 18 years of age will be enrolled into the study before the first adult participant has been treated with BAX 930 for a minimum of 6 months Participant has a documented diagnosis of severe hereditary deficiency, defined as Confirmed by molecular genetic testing, documented in participant history or at screening, and A disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity < 10 percent (%) as measured by the fluorescent resonance energy transfer von Willebrand factor73 (FRETS-VWF73) assay, documented in participant history or at screening (participants currently receiving standard of care (SoC) prophylactic therapy may exceed 10% activity at screening). Note: Participants currently receiving prophylactic therapy will be screened immediately prior to their usual prophylactic infusion Participant does not display any severe thrombotic thrombocytopenic purpura (TTP) signs (platelet count < 100,000/ microliter (mcL) and elevation of lactate dehydrogenase (LDH) greater than (>2)*upper limit of normal (ULN)) at screening. (Prophylactic cohort only) Participant is currently on a prophylactic dosing regimen or has a documented history of at least 1 TTP event and an ability to tolerate SoC prophylactic dosing (prophylactic cohort only) Participants >= 16 years of age must have a Karnofsky score >= 70% and participants < 16 years of age must have a Lansky score >= 80% Participant is hepatitis C virus (HCV)-negative as confirmed by antibody or polymerase chain reaction testing OR HCV-positive if their disease is chronic but stable  Participant has been diagnosed with any other TTP-like disorder (microangiopathic hemolytic anemia), including acquired TTP Participant has known hypersensitivity to hamster proteins Participant has experienced an acute TTP episode less than 30 days prior to screening (prophylactic cohort only) Participant has a medical history or presence of a functional inhibitor at screening Participant has a medical history of genetic or acquired immune deficiency that would interfere with the assessment of product immunogenicity, including participants who are human immunodeficiency virus (HIV)-positive with an absolute cluster of differentiation 4 (CD4) count < 200/ cubic millimeter (mm^3) or who are receiving chronic immunosuppressive drugs Participant has been diagnosed with severe cardiovascular disease (New York Heart Association classes 3 to 4) Participant with end stage renal disease requiring chronic dialysis Participant has been diagnosed with hepatic dysfunction, as evidenced by, but not limited to, any of the following Serum alanine aminotransferase (ALT) >= 2* upper limit of normal (ULN) Severe hypoalbuminemia < 24 gram per liter (g/L)